SEC Comment Letter for AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818) (AYTU) — Sep 17, 2018
AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818)
Date: Sept. 17, 2018 · CIK: 0001385818 · Accession: 0000000000-18-028974
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-227243
Letter
September 17, 2018 Joshua R. Disbrow Chairman and Chief Executive Officer Aytu Bioscience, Inc. 373 Inverness Parkway, Suite 206 Englewood, Colorado 80112 Re:Aytu Bioscience, Inc. Registration Statement on Form S-1 Filed September 7, 2018 File No. 333-227243 Dear Mr. Disbrow: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Michael R. Newton - Dorsey & Whitney LLP
Show Raw Text
September 17, 2018
Joshua R. Disbrow
Chairman and Chief Executive Officer
Aytu Bioscience, Inc.
373 Inverness Parkway, Suite 206
Englewood, Colorado 80112
Re:Aytu Bioscience, Inc.
Registration Statement on Form S-1
Filed September 7, 2018
File No. 333-227243
Dear Mr. Disbrow:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Michael R. Newton - Dorsey & Whitney LLP